FDA to Postpone Some Inspections of U.S. Manufacturing Facilities

As COVID-19 continues to spread, many companies and organizations are encouraging their employees to work remotely. This also applies to a number of U.S. regulatory bodies, including the U.S. Food and Drug Administration (FDA). On Wednesday, the FDA announced that due to many of its employees working remotely, it would be postponing routine inspections of American manufacturing facilities.

In 2019, the FDA conducted almost 12,300 inspections in the country across a variety of healthcare product categories, including drugs, medical devices, cosmetics, veterinary products, and more. However, the agency has decided to halt inspections due to safety concerns regarding its employees as well as preventing the potential spread of COVID-19. It will still conduct inspections it considers to be "mission critical."

Image source: Getty Images.

Continue reading

Source Fool.com